A detailed history of Black Rock Inc. transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 5,438,857 shares of SWTX stock, worth $205 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
5,438,857
Previous 5,382,184 1.05%
Holding current value
$205 Million
Previous $196 Million 36.27%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$36.5 - $52.5 $2.07 Million - $2.98 Million
56,673 Added 1.05%
5,438,857 $268 Million
Q4 2023

Feb 13, 2024

BUY
$18.94 - $37.24 $18.1 Million - $35.6 Million
956,452 Added 21.61%
5,382,184 $196 Million
Q3 2023

Nov 13, 2023

BUY
$23.12 - $31.38 $3.85 Million - $5.22 Million
166,341 Added 3.91%
4,425,732 $102 Million
Q2 2023

Aug 11, 2023

BUY
$23.15 - $32.71 $23.5 Million - $33.2 Million
1,015,359 Added 31.3%
4,259,391 $112 Million
Q1 2023

May 12, 2023

SELL
$24.97 - $34.05 $2.02 Million - $2.75 Million
-80,706 Reduced 2.43%
3,244,032 $83.5 Million
Q4 2022

Feb 13, 2023

BUY
$21.73 - $28.72 $10.9 Million - $14.5 Million
503,394 Added 17.84%
3,324,738 $86.5 Million
Q3 2022

Nov 14, 2022

BUY
$24.1 - $39.66 $4.87 Million - $8.01 Million
201,887 Added 7.71%
2,821,344 $80.5 Million
Q2 2022

Aug 12, 2022

BUY
$18.36 - $60.07 $5.81 Million - $19 Million
316,178 Added 13.73%
2,619,457 $64.5 Million
Q1 2022

May 12, 2022

SELL
$48.97 - $65.46 $2.86 Million - $3.82 Million
-58,373 Reduced 2.47%
2,303,279 $130 Million
Q4 2021

Feb 10, 2022

SELL
$53.3 - $75.84 $4.24 Million - $6.03 Million
-79,526 Reduced 3.26%
2,361,652 $146 Million
Q3 2021

Nov 09, 2021

SELL
$62.66 - $88.26 $2.83 Million - $3.98 Million
-45,145 Reduced 1.82%
2,441,178 $155 Million
Q2 2021

Aug 11, 2021

BUY
$67.45 - $85.63 $168 Million - $213 Million
2,486,323 New
2,486,323 $205 Million

Others Institutions Holding SWTX

About SpringWorks Therapeutics, Inc.


  • Ticker SWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,401,100
  • Market Cap $2.35B
  • Description
  • SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...
More about SWTX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.